Literature DB >> 18199515

Concurrent radiation therapy and bortezomib in myeloma patient.

Oscar Berges, Didier Decaudin, Vincent Servois, Youlia M Kirova.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18199515     DOI： 10.1016/j.radonc.2007.12.015

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN： 0167-8140            Impact factor:   6.280


× No keyword cloud information.
  5 in total

Review 1.  Manipulation of cellular redox parameters for improving therapeutic responses in B-cell lymphoma and multiple myeloma.

Authors:  Apollina Goel; Douglas R Spitz; George J Weiner
Journal:  J Cell Biochem       Date:  2012-02       Impact factor: 4.429

2.  Dexamethasone-induced oxidative stress enhances myeloma cell radiosensitization while sparing normal bone marrow hematopoiesis.

Authors:  Soumen Bera; Suzanne Greiner; Amit Choudhury; Angela Dispenzieri; Douglas R Spitz; Stephen J Russell; Apollina Goel
Journal:  Neoplasia       Date:  2010-12       Impact factor: 5.715

Review 3.  [Benefits of radiotherapy for patients with solitary plasmacytoma or multiple myeloma].

Authors:  Laila König; Klaus Herfarth
Journal:  Radiologe       Date:  2021-11-11       Impact factor: 0.635

4.  RR Myelo POINT: A Retrospective Single-Center Study Assessing the Role of Radiotherapy in the Management of Multiple Myeloma and Possible Interactions with Concurrent Systemic Treatment.

Authors:  Andrea Emanuele Guerini; Alessandra Tucci; Filippo Alongi; Eneida Mataj; Angelo Belotti; Paolo Borghetti; Luca Triggiani; Ludovica Pegurri; Sara Pedretti; Marco Bonù; Davide Tomasini; Jessica Imbrescia; Alessandra Donofrio; Giorgio Facheris; Navdeep Singh; Giulia Volpi; Cesare Tomasi; Stefano Maria Magrini; Luigi Spiazzi; Michela Buglione
Journal:  Cancers (Basel)       Date:  2022-05-02       Impact factor: 6.575

Review 5.  Clinical development of novel proteasome inhibitors for cancer treatment.

Authors:  Huanjie Yang; Jeffrey A Zonder; Q Ping Dou
Journal:  Expert Opin Investig Drugs       Date:  2009-07       Impact factor: 6.206
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.